(0.05%) 5 472.05 points
(0.09%) 39 148 points
(0.36%) 17 782 points
(0.01%) $80.84
(-3.66%) $2.66
(-0.80%) $2 312.10
(0.16%) $28.92
(3.51%) $1 021.00
(0.26%) $0.936
(0.67%) $10.67
(0.44%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States...
Stats | |
---|---|
今日成交量 | 910 216 |
平均成交量 | 262 784 |
市值 | 371 901 |
EPS | $-0.500 ( Q3 | 2023-11-14 ) |
下一个收益日期 | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.00462 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0290 (82.98%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-02-14 | Messinger Michael | Buy | 25 000 | Options (Right to Buy) |
2022-05-17 | Barlow Jane F | Buy | 42 000 | Options (Right to Buy) |
2022-05-17 | Sucoff Cary | Buy | 42 000 | Options (Right to Buy) |
2022-05-17 | Otto Michael J. | Buy | 42 000 | Options (Right to Buy) |
2022-05-17 | Low David N. | Buy | 42 000 | Options (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 55 transactions |
Buy: 2 642 000 | Sell: 9 700 000 |
音量 相关性
ContraFect Corp 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
ContraFect Corp 相关性 - 货币/商品
ContraFect Corp 财务报表
Annual | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-126.01 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-126.01 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.891 |
FY | 2020 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.240 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
ContraFect Corp
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。